WJB001 + paclitaxel + carboplatin

WJB001 + paclitaxel + carboplatin is an **experimental combination therapy** under investigation for the treatment of advanced solid tumors. This regimen consists of the investigational small molecule WJB001, paclitaxel (a microtubule inhibitor), and carboplatin (a platinum-based DNA-damaging agent). WJB001 is being developed as an oral agent and is evaluated for its safety, tolerability, pharmacokinetic properties, and preliminary antitumor efficacy, especially in tumors with CCNE1 overexpression or amplification, such as high-grade serous ovarian cancer, fallopian tube cancer, peritoneal cancer, and uterine serous carcinoma. The combination is currently in phase I/II clinical trials and is part of a broader protocol that also examines WJB001 paired with other agents. The precise molecular target and mechanism of action for WJB001 have not been explicitly detailed in public sources, but it is administered in combination with standard chemotherapeutics paclitaxel and carboplatin in multi-arm, dose-escalation, and expansion studies[1][3][5][6][7].